
FDA accepts Roche's giredestrant NDA for early-stage ER-positive breast cancer under priority review.
The FDA has accepted Roche's New Drug Application for giredestrant, an oral selective estrogen receptor degrader (SERD), as an adjuvant treatment for early-stage ER-positive, HER2-negative breast cancer. The approval decision is expected by November ...

